Results from a phases 3 trial enrolled prostate cancer patients with qualifying deleterious or suspected deleterious alterations in at least 1 of 15 prespecified genes in homologous recombination repair: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L, indicated that olaparib improved progression-free survival when compared with enzalutamide or abiraterone [38]. This evidence concerns the gene RAD51C and Familial prostate cancer.